Kos Pharmaceuticals: What the Prescriber Was Being Paid to Do

Whistleblower Justice Network

In the Kos Advicor Niaspan settlement, Kos Pharmaceuticals agreed to pay more than $38 million to settle civil allegations of prescription kickbacks and off-label promotion. The alleged benefits included money, free travel, grants and honoraria offered to get the drugs prescribed or recommended. The government also challenged a specific sales message for Advicor: use it first, for a treatment purpose Medicaid did not cover.

The Justice Department announced the settlement on December 7, 2010. Kos was an Abbott Laboratories subsidiary based in Delaware. This pharmaceutical fraud case joined two questions that people inside a drug company may see from different desks: what the company paid a prescriber to do, and what its sales force told that prescriber to do with the drug.

Niaspan was a brand-name prescription drug used primarily to treat lipid disorders. Kos developed it as a time-release version of niacin.

What Kos Allegedly Offered

The government alleged that Kos offered and paid benefits to doctors, other medical professionals, physician groups and managed care organizations to induce prescriptions or recommendations for Niaspan and Advicor. Its pharmaceutical kickback allegations reached money, free travel, grants, honoraria and other valuable goods and services. The recipient could be an individual prescriber or an organization influencing drug choices.

The expense category tells us how the payment was recorded. The communications around it tell us what the company expected to buy. The government’s allegation reached recommendations as well as prescriptions, so the person receiving the benefit did not have to be the one signing the prescription.

Drug marketing reaches directly into the prescribing decision through detailing, the industry’s term for promoting drugs to providers. The commercial attraction of a prescriber benefit is repeated prescription business. A manufacturer pays for the benefit, while a health care program can end up paying for the resulting drugs. The alleged bargain gave the company the prescriptions and left taxpayers with the bill. The healthcare decision was supposed to serve the patient.

For an insider, the useful question is what the payment actually bought. An honorarium agreement may describe a service. A sales discussion may describe a prescription target. The alleged exchange turns on the prescription business expected in return, whatever the payment was called.

When Speaking Invitations Follow Prescriptions

An allegation in a separate case against Novartis makes the prescription-for-benefit exchange unusually plain. A whistleblower alleged that the company assigned speaking opportunities by tracking how much Gilenya the speakers prescribed:

As further evidence of the corrupt marketing and sales philosophy pursued by NOVARTIS, if a speaker was not writing enough Gilenya prescriptions (i.e., scripts), NOVARTIS management quickly ensured that the speakers understood the true nature of the Patient Events. To this end, NPC tracked the prescriptions written by all physicians, including speakers, and evaluated the number of speaking engagements they should be given on the basis of the number of prescriptions of Gilenya written.

Whistleblower’s allegation, United States ex rel. Camburn v. Novartis Pharmaceuticals Corporation, complaint, paragraph 79

The alleged measure of a speaker’s value was how much the speaker prescribed. That is the connection worth examining in speaker program kickback cases: the selection decision, the payment and the prescription business expected in return.

Kos’s civil allegations put grants, honoraria and travel on the same side of that exchange. The Novartis complaint shows one alleged way a company could manage the exchange internally. For someone administering a speaker program or approving a grant, the reason a particular doctor kept getting paid may be the part of the story they know best.

Why Advicor’s First-Line Message Mattered

The government alleged that Kos promoted Advicor as first-line therapy, the starting treatment, for mixed dyslipidemias, a disruption of lipids in the blood. It said that use was neither approved by the Food and Drug Administration nor a medically accepted indication covered by federal and state Medicaid programs. The promotion allegation concerned Advicor specifically, while the inducement allegations concerned both Advicor and Niaspan.

That makes the treatment message central to the off-label promotion and false-claims question. The government’s contention was that Kos promoted that starting position for a use outside Medicaid coverage. The sales pitch and the program’s payment rules pointed in different directions.

The indication for which the drug was used helps explain whether the program would pay. In a case built around a first-line message, we connect the promotional instruction to the use it encouraged and the claims that followed.

That connection can require information from different systems. A May 2018 Managed Care article on indication-specific drug pricing describes a practical problem in drug-payment arrangements: the indication may be in the electronic medical record but absent from the information captured when the pharmacy dispenses the drug.

Applied to the Kos allegation, that is why the sales message, the treatment record and the payment record each matter.

The Civil Settlement and the Whistleblower Reward

The civil settlement allocated $33,705,310 to the federal government and $4,454,432 to state Medicaid programs.

The settlement resolved two qui tam lawsuits brought by former Kos employees. The Justice Department announced that the whistleblowers would receive more than $6.4 million collectively from the federal recovery.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. For pharmaceutical whistleblowers, the starting point is often knowledge of a business decision: why a benefit was approved, what a prescriber was expected to deliver, or which use the company wanted its sales force to promote.

What Evidence Is Needed to Prove Fraud?

For a case involving prescriber benefits and first-line promotion, the useful evidence connects the company’s payments and sales instructions to prescriptions and government claims. We examine the business purpose behind the benefit, the message behind the prescription, and the payment that followed.

Someone in sales may know the expected message. Someone approving expenses may know the payment’s purpose. Someone working with reimbursement may understand how the promoted use reached a claim. We work through those records with the insider who understands the business, connecting the payment’s purpose to the prescriptions it was meant to produce.

You Know What the Payment Was For

If you know why a prescriber received a grant, a trip or an honorarium, or how a first-line sales message reached government-paid prescriptions, speak to one of our whistleblower experts about what the payment bought. We build the case with you and bring in pharmaceutical fraud whistleblower lawyers who understand prescriber payments and drug reimbursement. We stay beside you as we turn that knowledge into your strongest pharmaceutical whistleblower case.

WHISTLEBLOWER JUSTICE NETWORK CAN HELP YOU
Make a difference.
Whistleblower Justice NetworkReport Fraud
100% CONFIDENTIALFREE CONSULTATION24 / 7 / 365